

Christian Michel Zwaan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3043527/publications.pdf>

Version: 2024-02-01

108
papers

4,846
citations

172457

29
h-index

102487

66
g-index

111
all docs

111
docs citations

111
times ranked

7529
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	1.4	451
2	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. <i>Nature Genetics</i> , 2015, 47, 330-337.	21.4	405
3	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
4	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	1.6	277
5	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
6	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	21.4	215
7	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 683-697.	16.8	213
8	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology</i> , The, 2015, 16, 465-474.	10.7	177
9	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	1.6	169
10	Pediatric AML: From Biology to Clinical Management. <i>Journal of Clinical Medicine</i> , 2015, 4, 127-149.	2.4	152
11	Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. <i>Nature Genetics</i> , 2017, 49, 451-456.	21.4	152
12	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <i>Nature Communications</i> , 2018, 9, 3962.	12.8	142
13	The biology of pediatric acute megakaryoblastic leukemia. <i>Blood</i> , 2015, 126, 943-949.	1.4	105
14	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1478-1487.	3.5	102
15	Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults. <i>Cancer</i> , 2012, 118, 4892-4900.	4.1	101
16	CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 134-142.	1.5	82
17	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 385-394.	10.7	80
18	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. <i>British Journal of Haematology</i> , 2010, 148, 768-776.	2.5	75

#	ARTICLE	IF	CITATIONS
19	Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. <i>Journal of Clinical Oncology</i> , 2013, 31, 2460-2468.	1.6	75
20	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.	1.4	64
21	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 735-745.	7.2	56
22	Motivations of children and their parents to participate in drug research: a systematic review. <i>European Journal of Pediatrics</i> , 2016, 175, 599-612.	2.7	52
23	Acute Leukemias in Children with Down Syndrome. <i>Pediatric Clinics of North America</i> , 2008, 55, 53-70.	1.8	49
24	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. <i>European Journal of Cancer</i> , 2014, 50, 170-177.	2.8	47
25	Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial. <i>European Journal of Cancer</i> , 2015, 51, 2031-2038.	2.8	42
26	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. <i>Cancer Research</i> , 2017, 77, 2102-2111.	0.9	41
27	Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. <i>Leukemia</i> , 2021, 35, 2978-2982.	7.2	40
28	Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. <i>Blood Advances</i> , 2018, 2, 1532-1540.	5.2	36
29	Acute Leukemias in Children with Down Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 19-34.	2.2	35
30	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	3.5	34
31	Key factors in children's competence to consent to clinical research. <i>BMC Medical Ethics</i> , 2015, 16, 74.	2.4	30
32	Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation. <i>Journal of Medical Genetics</i> , 2017, 54, 805-808.	3.2	30
33	ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27645.	1.5	29
34	Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2018, 183, 512-516.	2.5	27
35	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	12.8	26
36	Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-cell lineage acute lymphoblastic leukaemia or T-cell lineage lymphoblastic lymphoma: results of a phase 4 study. <i>British Journal of Haematology</i> , 2017, 179, 284-293.	2.5	25

#	ARTICLE	IF	CITATIONS
37	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. <i>Haematologica</i> , 2018, 103, 1484-1492.	3.5	24
38	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
39	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. <i>European Journal of Cancer</i> , 2022, 164, 1-17.	2.8	24
40	Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. <i>Blood Advances</i> , 2019, 3, 3307-3321.	5.2	23
41	A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 623-627.	2.5	23
42	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. <i>British Journal of Haematology</i> , 2014, 166, 902-910.	2.5	22
43	Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in <sc><i>ZMYND11/MBTD1</i></sc> fusion. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 237-241.	2.8	22
44	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28061.	1.5	21
45	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 70-70.	1.4	20
46	BCOR and BCORL1 mutations in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e194-e195.	3.5	19
47	Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s. <i>European Journal of Cancer</i> , 2021, 157, 81-93.	2.8	19
48	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3703-3703.	1.4	19
49	<i>PHF6</i> mutations in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 967-971.	2.5	18
50	<i>NUP98</i>-<i>BPTF</i> gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 311-319.	2.8	18
51	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1034-1043.	2.1	18
52	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28032.	1.5	17
53	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. <i>Blood</i> , 2014, 124, 2292-2292.	1.4	17
54	Replication timing alterations in leukemia affect clinically relevant chromosome domains. <i>Blood Advances</i> , 2019, 3, 3201-3213.	5.2	15

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10001-10001.	1.6	15
56	Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2019, 10, 2789.	12.8	14
57	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.0	14
58	Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015. <i>British Journal of Haematology</i> , 2020, 189, 1093-1106.	2.5	13
59	An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 523-527.	2.5	12
60	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	3.1	12
61	Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e130-e132.	3.5	11
62	Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia. <i>Psychoneuroendocrinology</i> , 2016, 72, 190-195.	2.7	11
63	Classification of pediatric acute myeloid leukemia based on miRNA expression profiles. <i>Oncotarget</i> , 2017, 8, 33078-33085.	1.8	11
64	High frequency of copy number alterations in myeloid leukaemia of Down syndrome. <i>British Journal of Haematology</i> , 2012, 158, 800-803.	2.5	10
65	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. <i>Blood</i> , 2014, 124, 127-127.	1.4	9
66	Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3100-3100.	1.6	9
67	Cushing syndrome as a presenting symptom of renal tumors in children. <i>Pediatric Blood and Cancer</i> , 2009, 53, 211-213.	1.5	8
68	Pharmacokinetics and population pharmacokinetics in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28132.	1.5	7
69	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 757-757.	1.4	7
70	Whole Genome Sequence Analysis of 22 MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 69-69.	1.4	6
71	NADH Dehydrogenase Subunit 4 (ND4) Mutations in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1380-1380.	1.4	6
72	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Central nervous system disease in pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26782.	1.5	5
74	Pediatric oncology as a <scp>Learning Health System: Ethical</scp> implications for best available treatment protocols. <i>Learning Health Systems</i> , 2018, 2, e10052.	2.0	5
75	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27273.	1.5	5
76	Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27785.	1.5	4
77	Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2005, 106, 107-107.	1.4	4
78	Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10030-10030.	1.6	4
79	<i>NUTM1</i>-Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study. <i>Blood</i> , 2020, 136, 25-26.	1.4	3
80	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2012, 120, 888-888.	1.4	3
81	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	3.5	3
82	A tale of two genes: a new connection between <i>NIPBL</i> and <i>NPM1</i> in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 1289-1291.	3.5	2
83	Voluntary Informed Consent Is Not Risk Dependent. <i>American Journal of Bioethics</i> , 2019, 19, 33-35.	0.9	2
84	Acute Megakaryoblastic Leukemia with Trisomy 21 and Tetrasomy 21 Clones in a Phenotypically Normal Child with Mosaic Trisomy 21. <i>Case Reports in Pediatrics</i> , 2020, 2020, 1-4.	0.4	2
85	Comprehensive Genomic Profiling of Pediatric Therapy-Related Myeloid Neoplasms Identifies Mecom Dysregulation to be Associated with Poor Outcome. <i>Blood</i> , 2019, 134, 1394-1394.	1.4	2
86	NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation.. <i>Blood</i> , 2007, 110, 757-757.	1.4	2
87	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.. <i>Blood</i> , 2006, 108, 734-734.	1.4	2
88	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. <i>Blood</i> , 2010, 116, 762-762.	1.4	2
89	Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype.. <i>Blood</i> , 2007, 110, 366-366.	1.4	1
90	Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-Analysis of 1929 Cases of Leukemia and Lymphoma.. <i>Blood</i> , 2007, 110, 3471-3471.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing. <i>Blood</i> , 2014, 124, 1887-1887.	1.4	1
92	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. <i>Blood</i> , 2018, 132, 290-290.	1.4	1
93	KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia Cells Undergo ER-Stress-Induced Apoptosis Following Exposure to Proteasome Inhibitors. <i>Blood</i> , 2019, 134, 1283-1283.	1.4	1
94	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. <i>Blood</i> , 2019, 134, 1429-1429.	1.4	1
95	The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
96	Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes. <i>Journal of Clinical Immunology</i> , 0, , .	3.8	1
97	Single-Cell RNA Sequencing Reveals a Developmental Hierarchy in Langerhans Cell Histiocytosis. <i>Cancer Discovery</i> , 2019, 9, 1343-1345.	9.4	0
98	Absence of JAK2 V617F Activating Mutations in Children with Acute Megakaryoblastic Leukemia with and without Down Syndrome.. <i>Blood</i> , 2006, 108, 4325-4325.	1.4	0
99	FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.. <i>Blood</i> , 2006, 108, 1359-1359.	1.4	0
100	Dexamethasone-Based Treatment and the Risk of CNS-Relapse in Acute Lymphoblastic Leukemia: Results from DCOG Protocol ALL-9.. <i>Blood</i> , 2006, 108, 1867-1867.	1.4	0
101	Differences in Cyto- and Molecular Genetic Abnormalities between Children &2 Years and Older Children with Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 1830-1830.	1.4	0
102	Clinical and Prognostic Significance of Eosinophilia and Inv(16)/t(16;16) In Pediatric Acute Myelomonocytic Leukemia (AML-M4).. <i>Blood</i> , 2010, 116, 1664-1664.	1.4	0
103	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015, 126, 481-481.	1.4	0
104	Prevalence of RNA Editing Events Affecting Coding Regions in Pediatric Leukemia. <i>Blood</i> , 2016, 128, 3928-3928.	1.4	0
105	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
106	Non-Coding HOX Fusions in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2019, 134, 533-533.	1.4	0
107	Immunotherapy: genetically agnostic in BCP-ALL?. <i>Blood</i> , 2022, 139, 2093-2094.	1.4	0
108	Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6563-6563.	1.6	0